



ACTIVELY RECRUITING
Randomized Phase 3 Study of Zanzalintinib ± Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) vs Placebo in Patients with Stage II/III Colorectal Cancer with Molecular Residual Disease Following Definitive Therapy
ZANZALINTINIB AND THE COMBINATION OF ZANZALINTINIB AND MK-3475A IS NOT APPROVED FOR THE USE UNDER INVESTIGATION IN THIS TRIAL. SAFETY AND EFFICACY HAVE NOT BEEN ESTABLISHED.
Study Overview
Approximately 600 eligible patients with stage II/III CRC who have MRD after completing definitive therapies will be randomized in a 1:1:1 ratio to receive zanzalintinib + MK-3475A, zanzalintinib monotherapy, or placebo to evaluate the effect of zanzalintinib + MK-3475A and zanzalintinib monotherapy on DFS vs placebo.

Stratification Factors
-
Site: Colon vs rectal
-
Mean tumor molecules (MTM): <1 vs ≥1 MTM/mL
-
Timing of ctDNA positivity: ≤8 weeks vs >8 weeks after definitive therapy
Key Elgibility Criteria
-
Histologically confirmed stage II/III adenocarcinoma of the colon or rectum
-
Documented MSS, MSI-low, or pMMR status
-
Completion of definitive therapy (R0 resection and ≥3 months of oxaliplatin‑containing neoadjuvant and/or adjuvant chemotherapy)
-
ctDNA-positive based on the Natera Signatera tissue-informed MRD assay
-
No evidence of radiographic disease
-
No prior treatment with ICIs or VEGFR inhibitors
Key Endpoints
Primary Endpoint
-
DFS by investigator (combination & monotherapy vs placebo)
Secondary Endpoints
-
Proportion of patients with ctDNA clearance
(combination & monotherapy vs placebo) -
OS
(combination & monotherapy vs placebo) -
DFS by investigator
(combination vs monotherapy) -
Safety and tolerability
Exploratory Endpoints
-
TTR by investigator
-
ctDNA dynamics
-
HRQoL by EORTC QLQ-C30
CRC, colorectal cancer; ctDNA, circulating tumor DNA; DFS, disease-free survival; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–Core 30; HRQoL, health-related quality of life; ICI, immune checkpoint inhibitor; MRD, molecular residual disease; MSI-low, microsatellite instability–low; MSS, microsatellite stable; MTM, mean tumor molecules; OS, overall survival; pMMR, proficient mismatch repair; q3w, once every 3 weeks; qd, once daily; SC, subcutaneous; TTR, time to recurrence; VEGFR, vascular endothelial growth factor receptor
Participating Sites
STELLAR-316 will be conducted in North America. Call 1-888-393-5494 (toll-free) or 1-303-389-1847 for specific location and site information and to confirm whether sites near you are still enrolling new patients.
Currently open or planned clinical site cities:
Trial sites may stop enrolling patients at any time. Please check back if you do not see a trial site located near you.





ACTIVE, NOT RECRUITING
Randomized Phase 3 Study of Zanzalintinib ± Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) vs Placebo in Patients with Stage II/III Colorectal Cancer with Molecular Residual Disease Following Definitive Therapy
ZANZALINTINIB AND THE COMBINATION OF ZANZALINTINIB AND MK-3475A IS NOT APPROVED FOR THE USE UNDER INVESTIGATION IN THIS TRIAL. SAFETY AND EFFICACY HAVE NOT BEEN ESTABLISHED.
